|Publication number||US7207965 B2|
|Application number||US 10/869,166|
|Publication date||24 Apr 2007|
|Filing date||16 Jun 2004|
|Priority date||16 Jun 2003|
|Also published as||CA2529495A1, CA2529495C, EP1638508A2, EP1638508A4, EP1638508B1, US20040254521, WO2004110391A2, WO2004110391A3|
|Publication number||10869166, 869166, US 7207965 B2, US 7207965B2, US-B2-7207965, US7207965 B2, US7207965B2|
|Original Assignee||Solx, Inc.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (105), Non-Patent Citations (2), Referenced by (60), Classifications (5), Legal Events (8)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This application claims the benefit of U.S. Provisional Application No. 60/478,895, filed Jun. 16, 2003. This application is herein incorporated in its entirety by reference.
The present invention pertains to surgical treatments for glaucoma and methods for reducing intraocular pressure (IOP), and more particularly relates to an implantable shunt device for allowing aqueous outflows from the eye's anterior chamber and associated methods thereof.
Glaucoma is a major public health problem, affecting about two percent of the U.S. population and the third most common cause of blindness in the U.S. There are several forms of glaucoma however each results in elevated intraocular pressure (IOP) in the eye, which can cause progressive damage to the optic nerve, and both central and peripheral visual field loss. If the IOP remains high for an extended period of time, total vision loss can occur. The elevated IOP is caused by an imbalance in fluid inflows and outflows in the eye, and the pressure reduces the blood supply to the optic nerve. The principal objective of medical treatment is the lowering of intraocular pressure.
The anterior chamber of the eye contains the aqueous humor, a clear fluid that is produced continuously by the ciliary body around the lens. The constant flow of aqueous humor though the eye's front chamber exits through two different routes. A limited outflow occurs through the uveoscleral route, wherein fluid migrates outwardly between muscle fibers of the ciliary body. The primary aqueous outflow pathway is through the trabecular meshwork (TM) and the Schlemm's canal.
The trabecular meshwork is a filtering structure that extends around the circumference of the eye at the “angle”—the junction between the iris, sclera and cornea. The trabecular meshwork consists of layers of collagen webs that filter the outflows. The meshwork has a monolayer of trabecular cells that produce enzymes for degrading extracellular material that may be captured by the filtering structure.
Aqueous humor that passes through the trabecular meshwork flows into Schlemm's canal, which is a passageway or series of septae that extend around the circumference of the eye adjacent to the meshwork. The aqueous fluid thereafter flows through a series of collecting channels that drain from Schlemm's canal and into the episcleral venous system. In a normal eye, aqueous production by the ciliary body is equal to aqueous outflows to provide an IOP that remains constant in the 15 to 21 mm Hg range. In a patient suffering from glaucoma, the resistance through the outflow system is typically greater than 21 mm Hg. In primary open angle glaucoma (POAG), the most common form of glaucoma, the principal resistance to fluid outflow is centered about the region of trabecular meshwork that is adjacent Schlemm's canal. It is believed that an abnormal trabecular cell metabolism results in compacted meshwork layers or a build up of extracellular materials within the meshwork that inhibits fluid flows.
Numerous therapies have been developed for treating glaucoma by decreasing intraocular pressure. Pharmacological therapies include topical ophthalmic drops and oral medications that reduce the production of aqueous by the ciliary body or increase aqueous outflows via the uveoscleral route. The treatments generally require applications at least daily and are relatively expensive. Furthermore, drugs may have occasional serious side effects, such as blurred vision, allergic reactions, headaches and potentially dangerous interactions with other drugs.
Surgical approaches for treating open-angle glaucoma consist of laser trabeculoplasty, trabeculectomy, and the implantation of aqueous shunts. Trabeculectomy is a widely practiced surgery wherein microsurgical techniques are used to dissect the trabecular meshwork to allow more rapid aqueous outflow through the meshwork. The benefits of the dissection procedures diminish over time due to the body's wound healing response and resulting fibrosis that repairs and closes the dissected opening in the meshwork. After the dissections are healed up, the intraocular pressure again increases. Thus these expensive procedures do not provide a long-lasting cure.
Implantable shunts and surgical methods are also known for providing a fluid path for aqueous humor to exit the anterior chamber of the eye to the sclera or a space beneath the conjunctiva. See e.g., U.S. Pat. No. 6,050,970 to Baerveldt.
Trabeculectomies and shunt surgeries and variations thereof have several disadvantages and moderate success rates. Such surgeries require significant surgical skills to create an incision through the full thickness of the sclera into the subconjunctival space. Further, the surgeries cause substantial trauma to the eye. The procedures are generally performed in an operating room and have a prolonged recovery time. Thus, the state of the art shunts and surgical techniques have yet to provide a cost-effective and long-lasting solution which has short recovery periods and low risk.
What are needed, therefore, are devices and techniques for successful, long-term reduction in intraocular pressure.
One embodiment of the present invention provides a system for reducing intraocular hypertension, the system comprising an implantable shunt. The implantable shunt comprises a planar member and at least one microchannel disposed within the planar member. There is an inflow port disposed proximate to a first end of the microchannel and an outflow port disposed proximate to a second end of the microchannel, wherein the inflow port is configured such that when the implantable shunt is implanted, the inflow port is located about approximately within the region of an angle of an anterior chamber.
Another embodiment of the present invention provides such a system wherein the outflow port is disposed in a plane, that plane being chosen from the group consisting of a suprachoroidal plane and a suprascleral plane.
A further embodiment of the present invention provides such a system wherein the planar member has a thickness less than 50 microns.
Still another embodiment of the present invention provides such a system wherein the thickness of the planar member is between 5 and 25 microns.
A still further embodiment of the present invention provides such a system further comprising at least one anchor.
Even another embodiment of the present invention provides such a system wherein the anchor is selected from the group consisting of barbs, hooks, and sutures.
An even further embodiment of the present invention provides such a system further comprising at least one reservoir communicating with the first end of the microchannel. Yet another embodiment of the present invention provides such a system further comprising at least one reservoir communicating with the second end of the microchannel.
A yet further embodiment of the present invention provides such a system wherein the at least one microchannel comprises fewer than 200 microchannels. An even further embodiment provides such a system wherein the at least one microchannel comprises between 10 and 100 microchannels.
Still even another embodiment of the present invention provides such a system further comprising at least one sacrificial microchannel closure. A still even further embodiment of the present invention provides such a system wherein the closure is photo-ablatable. Yet even another embodiment of the present invention provides such a system wherein the closure is doped with chromophores.
Still yet another embodiment of the present invention provides such a system wherein the system is comprised of at least one biocompatible material selected from the group of biocompatible material consisting of gold, platinum, titanium, nickel, molybdenum, biocompatible metals, biocompatible metal alloys, biocompatible ceramics, biocompatible polymers and combinations thereof.
One embodiment of the present invention provides a method for the reduction of intraocular pressure in an eye of a subject, the method comprising providing an implantable planar microchannel shunt, implanting the shunt in the eye, such that a first end of the shunt is disposed proximate to an angle of an anterior chamber of the eye, and permitting aqueous flows to migrate from the anterior chamber through at least one microchannel disposed within the shunt.
Another embodiment of the present invention provides such a method further comprising photo-ablating tissue disposed between the first end and the anterior channel. A further embodiment provides such a method wherein photo-ablating tissue disposed between the first end and the anterior channel comprises retracting tissue anterior to the first end of the shunt, and photo-ablating an intervening tissue layer with a laser, such as an excimer laser or a titanium sapphire laser.
Even another embodiment of the present invention provides such a method further comprising photo-ablating a sacrificial microchannel closure, thereby increasing flow of the aqueous flow through the shunt. An even further embodiment provides such a method wherein photo-ablating the sacrificial microchannel closure comprises using a goniolens.
The features and advantages described herein are not all-inclusive and, in particular, many additional features and advantages will be apparent to one of ordinary skill in the art in view of the drawings, specification, and claims. Moreover, it should be noted that the language used in the specification has been principally selected for readability and instructional purposes, and not to limit the scope of the inventive subject matter.
One embodiment of the present invention comprises a thin planar shunt device that can have various shapes and configurations as depicted in
In this particular embodiment the shunt device is shown having a substantially planar body 102. However, the various embodiments of the present invention encompass generally planar bodies including convex bodies, concave bodies, and bodies of variable thickness as well as substantially planar bodies. For example, the body 102 can employ a wedge shape such that the thickness of the first end section 106A differs from the thickness of the second end section 106B. This includes variations of thickness throughout the first end section 106A, the medial section 107 and the second end section 106B along the longitudinal axis 105 as well as from side to side.
The shunt 100A has a plurality of microchannels 110 (collectively) each extending from an inflow port 112A in the first end section 106A to an outflow port 112B in the second end section 106B. The shunt 100A of
In some embodiments there are one or more microchannels 110 that are coupled between the endwise edges 104A, 104B with or without intersecting the reservoirs 115A, 115B. The endwise edges 104A, 104B of the microchannels can be open to allow additional fluid flow or closed at the endwise edge 104A, 104B depending upon the application. It should also be understood that the microchannel thickness can be uniform or non-uniform to include aspects wherein the area of the microchannel at the inflow port 112A is different that the area of the microchannel at the outflow port 112B.
The inflow and outflow ports, 112A and 112B, of the microchannels 110 are disposed generally about the periphery of the open portions or reservoirs 115A and 115B. The open portions 115A and 115B, in some embodiments, are adapted to provide a sufficient spacing or area to help insure that tissue is not excessively compressed against the inflow and outflow ports 112A, 112B which might limit fluid flow through the microchannels 110. The placement, size and shape of the reservoirs 115A, 115B can be varied to establish a long-lasting and satisfactory flow of fluid.
As depicted in
One embodiment of the present invention has been designed with the further aspect related to the prevention of wounds and intended to aid in the healing process. As in intravascular stents, coatings and additives may be applied, such as those used to prevent restenosis resulting from scarring and wound healing. Such coatings are familiar to one skilled in the art of medical devices, and may be mineral or ceramic coatings, pharmaceutical coatings, radiological coatings, polymer coatings, metallic coatings and combinations thereof. According to one embodiment, the use of selected materials and of any coatings is intended to reduce or minimize the attachment of tissue to the shunt and allow for fluidic flow about the shunt.
The shape of the shunt, according to one embodiment, has also incorporated certain features, such as rounded edges as opposed to sharp edges, to aid in preventing tissue from attaching to the shunt. Sharp edges on implants allow fibroblasts to adhere to the shunt, facilitating the growth of scar tissue around the shunt and the healing of the wound, while smooth edges do not provide such favorable sites for adhesion. Scar tissue is detrimental as is restricts flow of aqueous fluid into, out of, through and around the shunt, both from its increased density over ordinary structures in the angle of the anterior chamber, and from its healing of the wound. Fibroblasts may clog inlet ports and outlet ports of the shunt. The open wound itself permits the unobstructed flow of aqueous fluid into the shunt. The surgeon's adjustment of flow rate is, in part, effected by the unobstructed flow. Complete closure of the wound would inhibit the flow of aqueous, resulting in higher intraocular pressure than originally anticipated. Furthermore scarring around the shunt would complicate removal of the shunt should infection, clogging, or other occurrences render it inoperable and require its removal.
In some embodiments, such as that illustrated in
Now referring to
The width W of the implant body 102 ranges, in various embodiments, between about 0.5 mm. and 5.0 mm, and according to one embodiment is from about 1.0 mm to 4.0 mm. The length L, in various embodiments, ranges between about 2.0 mm. and 10.0 mm, and, in some embodiments, is about approximately between 4.0 mm and 8.0 mm. The thickness of the shunt body ranges, in various embodiments and shapes, from about 2 microns to 50 microns, and, in some embodiments, is about approximately between 5 microns and 20 microns. The number of microchannels 110 in the shunt body typically can range from one to a hundred or more.
In one embodiment the shunt is intended for a target IOP in the range of 8–16 mmHg. This is a working range for the operation of the shunt and the shunt is designed accordingly. There are fluid dynamic principles that assist in determining the characteristics of the microchannels and the number of microchannels required for a given application utilizing variable such as the IOP pressure, flow rate and the properties of the liquid.
According to one embodiment, the shunt is designed to operate in the target IOP employing about 60% of the microchannels being open to the fluid flow and about 40% closed. This allows the doctor to open additional channels as described herein as necessary to optimally maintain the IOP in the target range, this permits modulation, or in situ adjustment of flow rates to achieve optimal intraocular pressure. As such, the implant is able to modulate the fluid flow once the shunt is inserted in the eye, not merely avoiding excessively low intraocular pressures.
The alternative shunt 100E of
Now turning to
Now referring to
As can be seen in
In one embodiment, as can be understood from
Now turning to
As can be understood from
The lower body portion 102 b shows open microchannels 315 that connect the reservoirs 115A, 115B, as well as closed microchannels 310. In one embodiment the closed channels 310 are located at the inflow reservoirs 115A and are selectively openable. It is also within the scope of the invention to have open microchannels 315 that are selectively closeable by introducing a blockage or otherwise deliberately restricting channels based upon the IOP. There are various schemes to open and close the microchannels as known in the art or otherwise described herein. In one embodiment the open and closed microchannels 310, 315 are about 50 microns wide with 50 micron spacing.
An additional aspect of the invention is the use of a manipulation hole 340 that aids in holding the shunt 100 g during the insertion or extraction process. The oversized hole 340 provides the ability to grasp the shunt 100 g with an insertion tool (not shown). While a manipulation hole 340 is shown, there are various other manipulation feature that may be used in conjunction with the insertion tool.
In further embodiment there are one or more front channels 330 that provide additional fluid flow at the endwise edges and in one embodiment the front channels 330 are 50 microns wide and spaced approximately 350 microns apart. There may also at least one side channel 335 that can be formed on any or all of the sides of the shunt 100G to further allow fluid flow. In one embodiment the side channels 335 are 50 microns wide with 50 micron spacing on the inflow end and 50 microns wide with 150 micron spacing on the outflow reservoir. It should be understood that the number and size of the front and side channels is dependent upon the desired application.
As the shunt 100 g is intended as a less costly mechanism for glaucoma treatment, the present invention has been designed with ease of manufacturing as an additional feature. The size of the holes and channels take into account the capabilities of the manufacturing processes currently available. Improved manufacturing capabilities may alter certain attributes of the shunt and the present description is not to be limited accordingly.
The foregoing description of the embodiments of the invention has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed. Many modifications and variations are possible in light of this disclosure. It is intended that the scope of the invention be limited not by this detailed description, but rather by the claims appended hereto.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US2134152||6 Jan 1937||25 Oct 1938||Ludwig Schwarzmayr||Wound drain-strip|
|US3159161||14 Nov 1962||1 Dec 1964||Alton Ness Richard||Fistulizing canaliculus|
|US3767759||19 May 1971||23 Oct 1973||Akademie Ved||Method of molding capillary drain for surgery|
|US3860008||3 Oct 1973||14 Jan 1975||Dow Corning||Flat drain|
|US3915172||26 Mar 1973||28 Oct 1975||Ceskoslovenska Akademie Ved||Capillary drain for glaucoma|
|US4377169||10 Jun 1981||22 Mar 1983||Banks Bruce A||Ion beam sputter-etched ventricular catheter for hydrocephalus shunt|
|US4391275||28 Nov 1980||5 Jul 1983||Lasag Ag||Method for the surgical treatment of the eye|
|US4428746||29 Jul 1981||31 Jan 1984||Antonio Mendez||Glaucoma treatment device|
|US4457757||20 Jul 1981||3 Jul 1984||Molteno Anthony C B||Device for draining aqueous humour|
|US4521210 *||27 Dec 1982||4 Jun 1985||Wong Vernon G||Eye implant for relieving glaucoma, and device and method for use therewith|
|US4558698||1 Mar 1984||17 Dec 1985||Dell Lawrence W O||Laser canaliculostomy eye-treatment|
|US4560375||30 Jan 1984||24 Dec 1985||Pudenz-Schulte Medical Research Corp.||Flow control valve|
|US4604087||21 Jun 1985||5 Aug 1986||Joseph Neil H||Aqueous humor drainage device|
|US4633866||22 Apr 1982||6 Jan 1987||Gholam Peyman||Ophthalmic laser surgical method|
|US4722724 *||23 Jun 1986||2 Feb 1988||Stanley Schocket||Anterior chamber tube shunt to an encircling band, and related surgical procedure|
|US4741730||4 Oct 1982||3 May 1988||American Hospital Supply||Hydrocephalus shunt with in-line filter|
|US4795437||29 Jan 1987||3 Jan 1989||Pudenz-Schulte Medical Research Corporation||Siphon control device|
|US4846172||26 May 1987||11 Jul 1989||Berlin Michael S||Laser-delivery eye-treatment method|
|US4850955||2 Dec 1986||25 Jul 1989||Codman & Shurtleff||Body fluid transfer device|
|US4957481||3 Jul 1989||18 Sep 1990||U.S. Bioscience||Photodynamic therapeutic technique|
|US5053006||2 Apr 1990||1 Oct 1991||Watson Brant D||Method for the permanent occlusion of arteries|
|US5129895||16 May 1990||14 Jul 1992||Sunrise Technologies, Inc.||Laser sclerostomy procedure|
|US5169395||26 Apr 1991||8 Dec 1992||Pdt Cardiovascular, Inc.||Laser delivery system|
|US5171213||14 Aug 1991||15 Dec 1992||Price Jr Francis W||Technique for fistulization of the eye and an eye filtration prosthesis useful therefor|
|US5222952||25 Jun 1992||29 Jun 1993||Hanspeter Loertscher||Method for laser sclerostomy|
|US5259380||15 Nov 1990||9 Nov 1993||Amcor Electronics, Ltd.||Light therapy system|
|US5292362||9 Jul 1991||8 Mar 1994||The Trustees Of Columbia University In The City Of New York||Tissue bonding and sealing composition and method of using the same|
|US5338291||3 Feb 1993||16 Aug 1994||Pudenz-Schulte Medical Research Corporation||Glaucoma shunt and method for draining aqueous humor|
|US5342370||19 Mar 1993||30 Aug 1994||University Of Miami||Method and apparatus for implanting an artifical meshwork in glaucoma surgery|
|US5346464||14 Apr 1993||13 Sep 1994||Camras Carl B||Method and apparatus for reducing intraocular pressure|
|US5346497||25 Aug 1993||13 Sep 1994||The University Of Miami||Surgical cutting head with asymmetrical cutting notch|
|US5370641||22 May 1992||6 Dec 1994||O'donnell, Jr.; Francis E.||Laser trabeculodissection|
|US5372595||7 Oct 1993||13 Dec 1994||Georgetown University||Contact probe for laser cyclophotocoagulation|
|US5385541||24 Apr 1992||31 Jan 1995||Loma Linda University Medical Center||Cerebrospinal fluid shunt capable of minimal invasive revision|
|US5397300||21 Apr 1994||14 Mar 1995||Iovision, Inc.||Glaucoma implant|
|US5411473||1 Oct 1991||2 May 1995||Ahmed; A. Mateen||Medical valve|
|US5423800||22 Sep 1993||13 Jun 1995||The University Of Miami||Laser scleral buckling method and instruments therefor|
|US5431646||22 Apr 1992||11 Jul 1995||Sunrise Technologies||Optical fiber probe and laser sclerostomy procedure|
|US5433701||21 Dec 1994||18 Jul 1995||Rubinstein; Mark H.||Apparatus for reducing ocular pressure|
|US5434878||18 Mar 1994||18 Jul 1995||Brown University Research Foundation||Optical gain medium having doped nanocrystals of semiconductors and also optical scatterers|
|US5454796||10 Mar 1993||3 Oct 1995||Hood Laboratories||Device and method for controlling intraocular fluid pressure|
|US5480396||9 Dec 1994||2 Jan 1996||Simon; Gabriel||Laser beam ophthalmological surgery method and apparatus|
|US5520621||25 Jul 1994||28 May 1996||Carapace, Inc.||Water-permeable casting or splinting device and method of making same|
|US5549596||20 Oct 1995||27 Aug 1996||The General Hospital Corporation||Selective laser targeting of pigmented ocular cells|
|US5549598||22 May 1995||27 Aug 1996||O'donnell, Jr.; Francis E.||Glaucoma laser trabeculodissection|
|US5573544||3 Jun 1994||12 Nov 1996||University Of Miami||Artificial meshwork filter for glaucoma surgery|
|US5573773||2 Sep 1993||12 Nov 1996||Ciba Geigy Corporation||Stable highly concentrated formulations of fluorescein derivatives|
|US5576013||21 Mar 1995||19 Nov 1996||Eastern Virginia Medical School||Treating vascular and neoplastic tissues|
|US5599340||13 Nov 1995||4 Feb 1997||Simon; Gabriel||Laser beam ophthalmological surgery method and apparatus|
|US5601094||22 Nov 1994||11 Feb 1997||Reiss; George R.||Ophthalmic shunt|
|US5626558||5 May 1995||6 May 1997||Suson; John||Adjustable flow rate glaucoma shunt and method of using same|
|US5651782||13 Jun 1996||29 Jul 1997||University Of Miami||Method and apparatus for implanting an artificial meshwork in glaucoma surgery|
|US5676679||13 Jun 1996||14 Oct 1997||University Of Miami||Apparatus for implanting an artifical meshwork in glaucoma surgery|
|US5704907||11 Dec 1995||6 Jan 1998||Wound Healing Of Oklahoma||Method and apparatus for lowering the intraocular pressure of an eye|
|US5707986||14 Mar 1994||13 Jan 1998||Miller; Joan W.||Angiographic method using green porphyrins in primate eyes|
|US5709653||25 Jul 1996||20 Jan 1998||Cordis Corporation||Photodynamic therapy balloon catheter with microporous membrane|
|US5785674||20 Dec 1996||28 Jul 1998||Mateen; Ahmed Abdul||Device and method for treating glaucoma|
|US5851225||13 Nov 1996||22 Dec 1998||Spectra Science Corporation||Photoemitting catheters and other structures suitable for use in photo-dynamic therapy and other applications|
|US5865831||17 Apr 1996||2 Feb 1999||Premier Laser Systems, Inc.||Laser surgical procedures for treatment of glaucoma|
|US5882327||17 Apr 1997||16 Mar 1999||Jacob; Jean T.||Long-term glaucoma drainage implant|
|US5944748||25 Jul 1997||31 Aug 1999||Light Medicine, Inc.||Photodynamic therapy apparatus and methods|
|US5958348||28 Feb 1997||28 Sep 1999||Nanogram Corporation||Efficient production of particles by chemical reaction|
|US6007578||8 Oct 1997||28 Dec 1999||Ras Holding Corp||Scleral prosthesis for treatment of presbyopia and other eye disorders|
|US6030411||8 Apr 1998||29 Feb 2000||Spectra Science Corporation||Photoemitting catheters and other structures suitable for use in photo-dynamic therapy and other applications|
|US6050970||8 May 1997||18 Apr 2000||Pharmacia & Upjohn Company||Method and apparatus for inserting a glaucoma implant in an anterior and posterior segment of the eye|
|US6059772||8 Jan 1997||9 May 2000||Candela Corporation||Apparatus and method for treating glaucoma using a gonioscopic laser trabecular ablation procedure|
|US6077299||22 Jun 1998||20 Jun 2000||Eyetronic, Llc||Non-invasively adjustable valve implant for the drainage of aqueous humor in glaucoma|
|US6095147||1 Dec 1994||1 Aug 2000||The Regents Of The University Of California||Method for photo-altering a biological system to improve biological effect|
|US6096028||29 Jul 1998||1 Aug 2000||Alcon Laboratories, Inc.||Multi-slot laser surgery|
|US6102045||24 Dec 1997||15 Aug 2000||Premier Laser Systems, Inc.||Method and apparatus for lowering the intraocular pressure of an eye|
|US6110212||7 Feb 1997||29 Aug 2000||Kenton W. Gregory||Elastin and elastin-based materials|
|US6142990||13 Feb 1998||7 Nov 2000||Heidelberg Engineering Optische Messsysteme Gmbh||Medical apparatus, especially for reducing intraocular pressure|
|US6186628||1 Nov 1999||13 Feb 2001||Jozek F. Van de Velde||Scanning laser ophthalmoscope for selective therapeutic laser|
|US6207392||1 Mar 1999||27 Mar 2001||The Regents Of The University Of California||Semiconductor nanocrystal probes for biological applications and process for making and using such probes|
|US6251103||2 May 1994||26 Jun 2001||Michael S. Berlin||Photoablative laser eye-treatment method|
|US6261256 *||3 Oct 1997||17 Jul 2001||Abdul Mateen Ahmed||Pocket medical valve & method|
|US6344272||11 Mar 1998||5 Feb 2002||Wm. Marsh Rice University||Metal nanoshells|
|US6355046||12 Aug 1999||12 Mar 2002||Canon Staar Co., Inc.||Inserting device for deformable intraocular lens|
|US6423056||30 Dec 1999||23 Jul 2002||Ball Semiconductor, Inc.||Injectable thermal balls for tumor ablation|
|US6428811||14 Jul 2000||6 Aug 2002||Wm. Marsh Rice University||Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery|
|US6450984||26 Apr 2000||17 Sep 2002||Gmp Vision Solutions, Inc.||Shunt device and method for treating glaucoma|
|US6471666||24 Feb 2000||29 Oct 2002||Steven A. Odrich||Injectable glaucoma device|
|US6520955||28 Dec 2000||18 Feb 2003||Michael Reynard||Phacophotolysis method and apparatus|
|US6524330||27 Oct 2000||25 Feb 2003||Bahram Khoobehi||Method of ocular treatment|
|US6530944||8 Feb 2001||11 Mar 2003||Rice University||Optically-active nanoparticles for use in therapeutic and diagnostic methods|
|US6544208||29 Dec 2000||8 Apr 2003||C. Ross Ethier||Implantable shunt device|
|US6589203||1 Aug 2000||8 Jul 2003||Peter Mitrev||Glaucoma drainage device implant|
|US6600951||16 Dec 1999||29 Jul 2003||The General Hospital Corporation||Targeting of sebaceous follicles as a Treatment of sebaceous gland disorders|
|US6607522||16 Mar 2000||19 Aug 2003||General Hospital Corporation||Methods for tissue welding using laser-activated protein solders|
|US6626858||12 Sep 2002||30 Sep 2003||Gmp Vision Solutions, Inc.||Shunt device and method for treating glaucoma|
|US6638239||14 Apr 2000||28 Oct 2003||Glaukos Corporation||Apparatus and method for treating glaucoma|
|US6666841||2 May 2001||23 Dec 2003||Glaukos Corporation||Bifurcatable trabecular shunt for glaucoma treatment|
|US6736791||1 Nov 2000||18 May 2004||Glaukos Corporation||Glaucoma treatment device|
|US6749623||12 Jun 2000||15 Jun 2004||Richard A Hsi||Method and apparatus for catheter phototherapy with dose sensing|
|US6827700||27 May 2003||7 Dec 2004||Gmp Vision Solutions, Inc.||Shunt device and method for treating glaucoma|
|US6966888||13 Jan 2002||22 Nov 2005||Eagle Vision, Inc.||Sinus valved glaucoma shunt|
|US20020133168||18 Mar 2002||19 Sep 2002||Smedley Gregory T.||Applicator and methods for placing a trabecular shunt for glaucoma treatment|
|US20020156413||27 Apr 1999||24 Oct 2002||Stuart K. Williams||Glaucoma shunt and a method of making and surgically implanting the same|
|US20030212383||5 Jan 2001||13 Nov 2003||Dana Cote||System and methods for reducing intraocular pressure|
|US20040015140 *||21 Jul 2003||22 Jan 2004||Shields Milton B.||Uveoscleral drainage device|
|US20040039378||1 Jun 2001||26 Feb 2004||Lin Charles P.||Selective photocoagulation|
|US20040193262||3 Feb 2004||30 Sep 2004||Shadduck John H.||Implants for treating ocular hypertension, methods of use and methods of fabrication|
|US20040215126 *||22 Apr 2003||28 Oct 2004||Ahmed A. Mateen||Device for treating glaucoma & method of manufacture|
|US20040225250||5 May 2003||11 Nov 2004||Michael Yablonski||Internal shunt and method for treating glaucoma|
|US20040260227 *||16 Dec 2003||23 Dec 2004||Lisk James R.||Article and method for ocular aqueous drainage|
|1||"Aqueous Shunts-510(k) Submission", Nov. 16, 1998, pp. 1-20, U.S. Department of Health and Human Services.|
|2||Broadley, Mark et al., "Guidelines for Specifying Metal Medical Tubing", Medical Design News, Mar. 2003, pp. 1-4, Penton Media Inc., Cleveland, OH.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7740604||24 Sep 2007||22 Jun 2010||Ivantis, Inc.||Ocular implants for placement in schlemm's canal|
|US7815592||22 Apr 2008||19 Oct 2010||Transcend Medical, Inc.||Ocular pressure regulation|
|US7850638||22 Dec 2006||14 Dec 2010||Transcend Medical, Inc.||Ocular pressure regulation|
|US7862531 *||25 Jun 2004||4 Jan 2011||Optonol Ltd.||Flow regulating implants|
|US8034016||7 Dec 2007||11 Oct 2011||Optonol, Ltd.||Flow regulating implants and methods of implanting|
|US8109896||11 Feb 2008||7 Feb 2012||Optonol Ltd.||Devices and methods for opening fluid passageways|
|US8128588||22 Dec 2006||6 Mar 2012||Transcend Medical, Inc.||Ocular pressure regulation|
|US8167939||26 Sep 2011||1 May 2012||Transcend Medical, Inc.||Ocular implant with stiffness qualities, methods of implantation and system|
|US8172899||26 Sep 2011||8 May 2012||Transcend Medical, Inc.||Ocular implant with stiffness qualities, methods of implantation and system|
|US8262726||5 Oct 2010||11 Sep 2012||Transcend Medical, Inc.||Ocular implant with stiffness qualities, methods of implantation and system|
|US8267882||18 Sep 2012||Ivantis, Inc.||Methods and apparatus for treating glaucoma|
|US8282592||6 May 2010||9 Oct 2012||Ivantis, Inc.||Glaucoma treatment method|
|US8313454||26 Mar 2010||20 Nov 2012||Optonol Ltd.||Fluid drainage device, delivery device, and associated methods of use and manufacture|
|US8337509||7 Dec 2009||25 Dec 2012||Ivantis, Inc.||Methods and apparatus for delivering ocular implants into the eye|
|US8353856||5 Nov 2008||15 Jan 2013||Abbott Medical Optics Inc.||Glaucoma drainage shunts and methods of use|
|US8372026||3 Feb 2012||12 Feb 2013||Ivantis, Inc.||Ocular implant architectures|
|US8377122||27 Jan 2010||19 Feb 2013||Transcend Medical, Inc.||Ocular implant with stiffness qualities, methods of implantation and system|
|US8414518||21 Mar 2012||9 Apr 2013||Ivantis, Inc.||Glaucoma treatment method|
|US8425449||9 Jul 2010||23 Apr 2013||Ivantis, Inc.||Ocular implants and methods for delivering ocular implants into the eye|
|US8444588||23 Feb 2010||21 May 2013||Transcend Medical, Inc.||Internal shunt and method for treating glaucoma|
|US8486000||12 Nov 2004||16 Jul 2013||Transcend Medical, Inc.||Ocular pressure regulation|
|US8486086||7 Nov 2011||16 Jul 2013||Optonol, Ltd||Flow regulating implant, method of manufacture, and delivery device|
|US8512404||20 Nov 2007||20 Aug 2013||Ivantis, Inc.||Ocular implant delivery system and method|
|US8521273||29 Jan 2009||27 Aug 2013||Gilbert H. KLIMAN||Drug delivery devices, kits and methods therefor|
|US8529492||20 Dec 2010||10 Sep 2013||Trascend Medical, Inc.||Drug delivery devices and methods|
|US8529494||11 Sep 2012||10 Sep 2013||Ivantis, Inc.||Methods and apparatus for treating glaucoma|
|US8551166||19 Nov 2012||8 Oct 2013||Ivantis, Inc.||Methods and apparatus for delivering ocular implants into the eye|
|US8574294||16 Dec 2010||5 Nov 2013||Transcend Medical, Inc.||Ocular implant with stiffness qualities, methods of implantation and system|
|US8617139||25 Jun 2009||31 Dec 2013||Transcend Medical, Inc.||Ocular implant with shape change capabilities|
|US8636713||23 Apr 2012||28 Jan 2014||Emory University||Methods and devices for drug delivery to ocular tissue using microneedle|
|US8657776||14 Jun 2011||25 Feb 2014||Ivantis, Inc.||Ocular implants for delivery into the eye|
|US8663150||19 Dec 2011||4 Mar 2014||Ivantis, Inc.||Delivering ocular implants into the eye|
|US8672870||17 Jul 2008||18 Mar 2014||Transcend Medical, Inc.||Ocular implant with hydrogel expansion capabilities|
|US8702639||25 Mar 2010||22 Apr 2014||Abbott Medical Optics Inc.||Glaucoma shunts with flow management and improved surgical performance|
|US8721656 *||22 Dec 2006||13 May 2014||Transcend Medical, Inc.||Glaucoma treatment device|
|US8728021||17 Dec 2010||20 May 2014||Transcend Medical, Inc.||Ocular pressure regulation|
|US8734377||23 Sep 2008||27 May 2014||Ivantis, Inc.||Ocular implants with asymmetric flexibility|
|US8734378||17 Sep 2009||27 May 2014||Transcend Medical, Inc.||Glaucoma treatment device|
|US8758289||17 Dec 2010||24 Jun 2014||Transcend Medical, Inc.||Ocular pressure regulation|
|US8771218||17 Dec 2010||8 Jul 2014||Transcend Medical, Inc.||Ocular pressure regulation|
|US8801649||5 Oct 2010||12 Aug 2014||Transcend Medical, Inc.||Glaucoma treatment device|
|US8808220||14 Oct 2010||19 Aug 2014||Transcend Medical, Inc.||Ocular pressure regulation|
|US8808222||22 Aug 2013||19 Aug 2014||Ivantis, Inc.||Methods and apparatus for delivering ocular implants into the eye|
|US8808225||15 Apr 2012||19 Aug 2014||Emory University||Methods and devices for drug delivery to ocular tissue using microneedle|
|US8814819||16 Dec 2010||26 Aug 2014||Transcend Medical, Inc.||Glaucoma treatment device|
|US8920357||13 Dec 2012||30 Dec 2014||Abbott Medical Optics Inc.||Glaucoma drainage shunts and methods of use|
|US8926510||27 Apr 2012||6 Jan 2015||Istar Medical Sa||Device and method for glaucoma management and treatment|
|US8945038||17 May 2013||3 Feb 2015||Transcend Medical, Inc.||Internal shunt and method for treating glaucoma|
|US8961447||25 Feb 2013||24 Feb 2015||Ivantis, Inc.||Glaucoma treatment method|
|US9039650||7 Apr 2014||26 May 2015||Ivantis, Inc.||Ocular implants with asymmetric flexibility|
|US9050169||14 Jul 2014||9 Jun 2015||Ivantis, Inc.||Methods and apparatus for delivering ocular implants into the eye|
|US9066750||2 Jan 2014||30 Jun 2015||Ivantis, Inc.||Delivering ocular implants into the eye|
|US9066783||15 Aug 2013||30 Jun 2015||Ivantis, Inc.||Methods and apparatus for treating glaucoma|
|US9084662||17 Jan 2007||21 Jul 2015||Transcend Medical, Inc.||Drug delivery treatment device|
|US9089392||23 Aug 2013||28 Jul 2015||Transcend Medical, Inc.||Drug delivery devices and methods|
|US20050288617 *||25 Jun 2004||29 Dec 2005||Ira Yaron||Flow regulating implants|
|US20060069340 *||3 Nov 2005||30 Mar 2006||Solx, Inc.||Shunt for the treatment of glaucoma|
|US20070088242 *||12 Nov 2004||19 Apr 2007||Coroneo Minas T||Ocular pressure regulation|
|US20070191863 *||22 Dec 2006||16 Aug 2007||De Juan Eugene Jr||Glaucoma Treatment Device|
|EP2789318A2||25 Mar 2010||15 Oct 2014||Abbott Medical Optics Inc.||Glaucoma shunts with flow management and improved surgical performance|
|International Classification||A61M5/00, A61F9/007|
|2 Jul 2004||AS||Assignment|
Owner name: SOLX INC., MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SIMON, GABRIEL;REEL/FRAME:014814/0013
Effective date: 20040616
|31 Jan 2007||AS||Assignment|
Owner name: PETER M. ADAMS, DOUG P. ADAMS, AND JOHN SULLIVAN,
Free format text: SECURITY AGREEMENT;ASSIGNOR:SOLX, INC.;REEL/FRAME:018826/0382
Effective date: 20060901
|25 Jan 2008||AS||Assignment|
Owner name: DOUG P. ADAMS, JOHN SULLIVAN AND PETER M. ADAMS, C
Free format text: SECURITY AGREEMENT;ASSIGNOR:SOLX, INC.;REEL/FRAME:020403/0845
Effective date: 20080122
|28 Feb 2008||AS||Assignment|
Owner name: OCCULOGIX, INC., CANADA
Free format text: SECURITY AGREEMENT;ASSIGNOR:SOLX, INC.;REEL/FRAME:020571/0577
Effective date: 20080211
|5 Mar 2008||AS||Assignment|
Owner name: OCCULOGIX, INC., CANADA
Free format text: CORRECTING TYPOGRAPHICAL ERROR OF A PATENT NUMBER PREVIOUSLY RECORDED ON REEL/FRAME 020571/0577;ASSIGNOR:SOLX,INC.;REEL/FRAME:020599/0776
Effective date: 20080211
|24 Sep 2010||FPAY||Fee payment|
Year of fee payment: 4
|15 Oct 2010||AS||Assignment|
Owner name: SOLX, INC., MASSACHUSETTS
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:TEARLAB CORPORATION (FORMERLY KNOWN AS OCCULOGIX, INC.);REEL/FRAME:025137/0719
Effective date: 20101014
Effective date: 20101014
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PETER M. ADAMS, DOUG P. ADAMS, AND JOHN SULLIVAN, COLLECTIVELY ASTHE STOCKHOLDER REPRESENTATIVE COMMITTEE, ON BEHALF OF THE PARTICIPATING RIGHTS HOLDERS OF SOLX, INC.;REEL/FRAME:025137/0725
Owner name: SOLX, INC., MASSACHUSETTS
|2 May 2014||FPAY||Fee payment|
Year of fee payment: 8